Atlas Trials

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Clinical trial NCT03086330 · COMPLETED

Trial details

NCT number
NCT03086330
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2
Start date
2017-03-15
Primary completion
2018-07-04
Enrollment
302

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.